HPV 16 Infection
8
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Human Papillomavirus in Young People Epidemiological Research 4
Human Papillomavirus in Young People Epidemiological Research 3
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)